Vistin Pharma Logo

Vistin Pharma

A leading global producer of Metformin Hydrochloride for the global healthcare market.

VISTN | OL

Overview

Corporate Details

ISIN(s):
NO0010734122
LEI:
5967007LIEEXZXFQY092
Country:
Norway
Address:
Postboks 6735 Etterstad, 0609 Oslo
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vistin Pharma is a specialized pharmaceutical company and a leading global producer of Metformin Hydrochloride, the standard first-line treatment for Type 2 diabetes. The company operates as a pure-play metformin supplier, producing both Active Pharmaceutical Ingredients (API) and Direct Compressible (DC) grades for the global healthcare market. As a dedicated European manufacturer, Vistin Pharma is positioned to supply a significant portion of the world's demand for this essential medicine, with a focus on high-quality and sustainable production.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-31 07:40
Investor Presentation
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.7 MB
2025-10-31 07:40
Quarterly Report
Vistin Pharma ASA: Third quarter and YTD 2025 financial results - Attachment: V…
English 1.5 MB
2025-10-31 07:40
Earnings Release
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
English 2.2 KB
2025-10-24 10:00
Report Publication Announcement
Vistin Pharma ASA: Invitation to Q3 2025 conference call
English 2.6 KB
2025-08-15 08:00
Interim Report
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.6 MB
2025-08-15 08:00
Investor Presentation
Vistin Pharma ASA: Second quarter and YTD 2025 financial results - Attachment: …
English 1.9 MB
2025-08-15 08:00
Earnings Release
Vistin Pharma ASA: Second quarter and YTD 2025 financial results
English 2.1 KB
2025-08-08 10:00
Regulatory News Service
Vistin Pharma ASA: Invitation to Q2 2025 conference call
English 1.6 KB
2025-06-04 08:00
Notice of Dividend Amount
Ex dividend NOK 1.25 today
English 330 bytes
2025-05-23 09:22
Report Publication Announcement
Financial calendar
English 464 bytes
2025-05-23 09:22
Report Publication Announcement
Finansiell kalender
Norwegian 448 bytes
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 897.7 KB
2025-05-22 12:59
Post-Annual General Meeting Information
Vistin Pharma ASA: Minutes from the annual general meeting 2025
English 736 bytes
2025-05-22 09:56
Proxy Solicitation & Information Statement
Disclosure of voting rights at AGM in Vistin Pharma ASA
English 963 bytes
2025-05-07 13:30
Board/Management Information
Vistin Pharma ASA (VISTN): Update from the Election Committee
English 1.3 KB

Automate Your Workflow. Get a real-time feed of all Vistin Pharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vistin Pharma

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vistin Pharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.